Drastic antitumor response following administration of afatinib immediately after atezolizumab in a patient with epidermal growth factor receptor tyrosine kinase inhibitor‐resistant lung cancer
Main Authors: | Toshiyuki Sumi, Hisashi Nakata, Hirofumi Chiba |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-07-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.14047 |
Similar Items
-
Long‐term response to afatinib in an elderly patient with uncommon epidermal growth factor receptor mutation‐positive lung adenocarcinoma
by: Naoki Shijubou, et al.
Published: (2021-03-01) -
Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations
by: Tomomi Masuda, et al.
Published: (2020-08-01) -
Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the ‘panacea’ for all patients?
by: Alessandro Morabito
Published: (2018-02-01) -
Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer
by: Kazumi Sano, et al.
Published: (2020-04-01) -
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib
by: Sami Morin-Ben Abdallah, et al.
Published: (2017-05-01)